ReCode Therapeutics
Min Chen began their career in 2017 as a Postdoctoral Researcher at the University of California, Santa Cruz. In 2019, they moved to the University of California, San Francisco, where they served as a Postdoctoral Researcher until 2022. Currently, they are a Scientist at ReCode Therapeutics.
Min Chen completed a Doctor of Philosophy - PhD in Cell/Cellular and Molecular Biology from the University of Paris-Saclay between 2012 and 2017.
This person is not in the org chart
ReCode Therapeutics
1 followers
ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapies for patients with life-limiting respiratory diseases.